Closing the gap in HCV care: strategic collaboration between industry, academic, community, and nonprofit researchers
Increased funding for hepatitis C virus (HCV) research and care delivery is needed to support effective programs for vulnerable communities and meet the WHO 2030 targets for HCV elimination. Strategic collaborations among industry and non-industry stakeholders can address this need. Establishing clear expectations, transparency, and investigator independence in these partnerships can enhance and accelerate HCV elimination efforts. Similar collaborative partnerships can be extended to address challenges in other therapeutic areas.
Authors
- Alessandra Mangia (ORCID: https://orcid.org/0000-0002-2600-3555)
- Sunil S. Solomon (ORCID: https://orcid.org/0000-0002-3296-1514)
- Homie Razavi (ORCID: https://orcid.org/0000-0002-2658-6930)
- Ming‐Lung Yu (ORCID: https://orcid.org/0000-0001-8145-1900)
- Nancy S. Reau (ORCID: https://orcid.org/0000-0003-2290-4580)
- Jeffrey V. Lazarus (ORCID: https://orcid.org/0000-0001-9618-2299)
Institutions
- The Graduate Center, CUNY (US)
- Rush University Medical Center (US)
- Johns Hopkins University (US)
- Kaohsiung Medical University (TW)
- Johns Hopkins Medicine (US)
- Casa Sollievo della Sofferenza (IT)
- Kaohsiung Medical University Chung-Ho Memorial Hospital (TW)
- Barcelona Institute for Global Health (ES)
- Center for Disease Analysis (US)
Publication Details
- Journal
- npj gut and liver.
- Published
- 2025-09-03
- DOI
- https://doi.org/10.1038/s44355-025-00028-w
- Citations
- 1
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 1.32
Funders
- Gilead Sciences